BOSTON--(BUSINESS WIRE)--PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the CEO Roundtable on Cancer has again named PAREXEL a CEO Cancer Gold Standard™ employer. The biennial U.S.-based accreditation, which PAREXEL previously received in 2015, recognizes the Company’s strong commitment to the health of its employees and their families.
The Gold Standard provides a framework for employers to have healthier workplaces by focusing on cancer risk education, early detection, access to clinical trials and high-quality care. To earn the accreditation, companies must demonstrate concrete efforts to address cancer in the workplace. PAREXEL has several programs in place to help its employees reduce cancer risk, including:
- Promoting physical activity, healthy nutrition and weight management
- Offering a medical incentive program to reduce an employee’s health plan contribution costs following completion of health and wellness activities
- Providing health insurance options that include detection of cancer at its earliest stages, participation in cancer clinical trials and access to quality care
- Supporting the needs of cancer survivors in the workplace
- Prohibiting tobacco use and supporting cessation efforts
“At PAREXEL, our employees are the key to our success as we help our clients bring life-saving treatments to patients around the globe,” said Josef von Rickenbach, Chairman and CEO, PAREXEL. “We are honored that the CEO Roundtable on Cancer has once again named us a Gold Standard employer for our continued commitment to the health and well-being of our employees and their families.”
About the CEO Roundtable on Cancer
The CEO Roundtable on Cancer is a nonprofit organization of CEOs founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded by creating and encouraging the widespread adoption of the CEO Cancer Gold Standard™, which calls for organizations to evaluate their health benefits and workplace culture and take extensive, concrete actions in five key areas of health and wellness to address cancer in the workplace. For more information on the CEO Cancer Gold Standard and the no-cost, web-based accreditation process, please visit www.CancerGoldStandard.org.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world, and had approximately 19,370 employees in the third quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.